Gland Pharma informs about conclusion of US FDA inspection at pashamylaram facility

26 Sep 2023 Evaluate
Further to intimation dated June 27, 2023, Gland Pharma has informed that following the Pre-Approval Inspection (PAI) for Seven (7) products and Good Manufacturing Practice (GMP) Inspection by US FDA at the Company’s Pashamylaram Facility at Hyderabad between 15th June, 2023 and 27th June, 2023, the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

The above information is a part of company’s filings submitted to BSE.

Gland Pharma Share Price

1644.00 -9.35 (-0.57%)
29-Dec-2025 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1268.00
Cipla 1493.10
Zydus Lifesciences 904.25
Lupin 2078.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×